Evidence Hub

P-1320. Antimicrobial susceptibility of S. maltophilia and B. cepacia species complex isolated from patients with pneumonia in United States hospitals (2022-2024)

Helio SaderMarisa Winkler, Rodrigo Elisandro Mendes, Dmitri V. Debabov, Mariana Castanheira

Open Forum Infectious Diseases, 2026

Abstract

Abstract Background The occurrences of S. maltophilia and B. cepacia infections, mainly pneumonia, have increased continuously in the last few years. We evaluated the in vitro activities of aztreonam-avibactam (ATM-AVI) and comparators against S. maltophilia and B. cepacia causing pneumonia in United States medical centers.Table 1.Antimicrobial activity of selected antimicrobials against S. maltophilia and B. cepacia from patients with pneumonia.a CLSI (2025) breakpoints for Enterobacterales were applied for comparison for comparison.b Based on CLSI (2025) breakpoints for S. maltophilia.Aztreonam-avibactam MIC distributions for S. maltophilia and B. cepacia from patients with pneumonia Methods 958 clinical isolates, including 830 S. maltophilia and 128 B. cepacia, were consecutively collected from patients with pneumonia in 65 United States (US) medical centers in 2022-2024. Isolates were susceptibility tested by CLSI M07 broth microdilution. CLSI breakpoints were applied for S. maltophilia when available. Enterobacterales breakpoints were applied to B. cepacia and susceptible [S]/resistant breakpoints of ≤ 4/≥ 16 mg/L were applied for ATM-AVI against both organisms for comparison.Activity of aztreonam-avibactam and comparators against S. maltophilia resistant subsets.* % inhibited at ≤4 mg/L. ** % inhibited at ≤2 mg/L.Abbreviations: TMP-SMX, trimethoprim-sulfamethoxazole, NS, nonsusceptible. Results The most active agents against S. maltophilia were…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free